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Mysterious X Lymphocyte Cure to Type One Diabetes?
By George Qiao
Diabetes, the seventh leading cause of death
in the United States, is caused by excessive blood
glucose.1 Type 1 diabetes is a variation of the disease
characterized by a deficiency in insulin, a hormone
produced in the pancreas that allows cells to take up
glucose from the blood and receive energy. Lack of
insulin results in accumulation of sugar in the bloodstream, and subsequently dehydration, excessive
urination, and tissue damage.2 The need to prevent the
disease is urgent, as over a million children or young
adults in the world have type 1 diabetes, and over
100,000 cases of type 1 diabetes are diagnosed every
year.3 Type 1 diabetes is known as
an autoimmune disease because
the immune system destroys insulin-producing beta cells in the
pancreas.2 What is not certain is the
mechanism by which this occurs.
However, recent research has linked
the disease to a newly found cell
called the X lymphocyte.4
We are familiar with the B
and T lymphocytes, which are
involved in the acquired immune response in our
bodies for fighting against extracellular pathogens. B
cells function to secrete antibodies that recognize antigens and are involved in humoral immunity. During
maturation in the bone marrow, B cells that react
with self-antigens are negatively selected; that is, they
undergo apoptosis or receptor modification so that
they are not a threat to the body. The surviving B cells
then travel to the spleen to complete maturation and
become naive B cells, which are mature cells that are
not yet activated.5 T cells arrive in different classes and
fight against intracellular pathogens through cell-mediated immunity. During maturation in the thymus,

, T cells also undergo negative selection, and once matured, are known as naive T cells.6
Antigen-presenting cells (APCs) recognize
protein antigens and display them to T cells. A B cell
can act as an APC and recognize protein antigens using its B-cell receptor (BCR) to internalize the antigen
and process and display the antigen on an MHC II
molecule. A helper T cell can recognize the presented antigen through its T-cell receptor (TCR), and the
interaction between the MHC II on the B cell and CD4
molecule on the T cell results in T cell activation. The
T cell secretes cytokines that activate the B cell, which
differentiates into plasma cells that secrete antibodies and memory cells that
remain for future invaders.5 Cytotoxic
T cells, unlike helper T cells, directly
target pathogen-infected cells and destroy the cells along with the pathogen
inside.6
Normally, the only two types
of lymphocytes that the body produces are B and T lymphocytes. What is
previously known regarding the
mechanism of insulin destruction is that insulin can
bind to a molecule on APCs known as HLA-DQ8.
However, the binding is not strong enough to trigger
a reaction that leads to type 1 diabetes. Researchers at
Johns Hopkins Medicine recently utilized computer
simulations that revealed dual-expressor (DE) cells
which express both the BCR and TCR. A protein coded by the BCR of DE cells, named the x-Id peptide, can
bind to HLA-DQ8 very tightly compared to insulin,
and the binding is strong enough to bring out a T cell
response that can result in type 1 diabetes.4
To test the strength of the T cell response by
DE cells, the researchers produced a genetically-

engineered insulin mimic called the “superagonist,”
which has a higher affinity for HLA-DQ8 than normal
insulin and is 1,000 times more immune-stimulating.
The team ran computer simulations which illustrated
that the x-Id protein resulted in a T cell response with
tenfold increased strength over that of the superagonist; hence, the x-Id protein displayed a trigger in
T cell activity that is 10,000 times stronger than that
produced by normal insulin. These results suggest that
the x-Id protein found in DE cells can elicit strong T
cell responses that can then attack insulin-producing
cells.4, 7
To confirm the existence of the DE cell, which
can be referred to as the “X” lymphocyte, the researchers used a virus to produce genetically-identical duplicates of the cell, and found that the clone cells all expressed both BCRs and TCRs, illustrating that the cell
is a hybrid of the B cell and the T cell. Furthermore,
the researchers obtained blood samples from donors
with type 1 diabetes and healthy donors and found that
the DE lymphocytes appeared more frequently in patients with type 1 diabetes than nondiabetic subjects.4,
7

The discovery of the X lymphocyte helps
deepen our understanding of type 1 diabetes and can
be insightful for those searching for a cure for the
condition. While the results of the X lymphocyte study
at Johns Hopkins yields valuable information, more
studies should be done to further confirm and analyze
the new type of cell. In the future, more information
regarding the X lymphocyte and its behavior can bring
us closer to finding a cure for type 1 diabetes.
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